Nexi, developing an anti-cancer immunotherapy drug, attracts 4 billion won for Pre-A

On May 27, 2022 NEXI, is focusing on developing next-generation immunotherapy drugs, reported the company won 4 billion for Pre-A funding (Press release, NEX-I, MAY 27, 2022, View Source;mode=VIEW&num=17&category=&findType=&findWord=&sort1=&sort2=&page=3 [SID1234643434]). D.S.C.investment,Schmidt,Hana Ventures,Daewoong Pharmaceutical and others participated.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

DSCSchmidt, a subsidiary of Investment, has8We helped select the TIPS project along with the monthly seed investment.,Participated in this follow-up investment as well..

Daewoong Pharmaceutical is a strategic investor and plans to seek cooperation measures such as joint research with NexI in the future..

Kim YohanDSCHead of Investment Biotech Division"Although there are differences depending on the cancer type, the response rate of existing immunotherapy drugs is20~30%There is an unmet medical need for this due to low severity..Nexi decided to make this investment because it fits this global development trend."He said.

Pre-AThe investment is for NexI’s next-generation immuno-anticancer drug pipeline.’NXI-101’class’NXI-201’It will be used for research and development of.

Kyung-wan Yoon, CEO of Nexi"With this investment, we will actively recruit excellent talent and accelerate research and development of anti-cancer drugs..We will do our best for overseas partnering starting next year."said.

The company said"Based on its independently built platform technology, Nexi has discovered a number of factors that induce anti-cancer immunotherapy drug refractoriness.,targeting thisFirst-in-classDeveloping new antibody drugs"as"We plan to administer it alone or in combination to cancer patients who do not respond to immunotherapy.,Through this, we will overcome the limitations of low response rates of existing immunotherapy drugs."He said.

Nexi announced earlier this monthNXI-101Established by being selected for national new drug development project through research8After about a month4Has been selected for 10 national projects.